Exscientia Dirección

Dirección controles de criterios 1/4

El CEO de Exscientia es Dave Hallett, nombrado en Feb 2023, tiene una permanencia de 1.75 años. posee directamente un 0.001% de las acciones de la empresa, con un valor de €7.00K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 3.8 años, respectivamente.

Información clave

Dave Hallett

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.8yrs
Participación del CEO	0.001%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Dave Hallett (55 yo)

1.8yrs

Permanencia

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Hallett	Chief Scientific Officer	1.8yrs	sin datos	0.0011% € 7.0k
John Overington	Chief Technology Officer	less than a year	sin datos	0.015% € 91.1k
Sara Sherman	Vice President of Investor Relations	no data	sin datos	sin datos
Dan Ireland	Executive VP of Legal & Company Secretary	1.8yrs	sin datos	sin datos
Parker Moss	Executive Vice President of Corporate Development	less than a year	sin datos	sin datos
Caroline Rowland	Chief People Officer	2.2yrs	sin datos	sin datos
Richard Law	Chief Business Officer	no data	sin datos	sin datos
Nikolaus Krall	Executive Vice President of Precision Medicine	1.8yrs	sin datos	sin datos
Marie-Louise Fjallskog	Interim Chief Medical Officer & Clinical Development Lead	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0RK no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Hallett	Chief Scientific Officer	less than a year	sin datos	0.0011% € 7.0k
Elizabeth Crain	Independent Non-Executive Chairman	3.8yrs	UK£282.03k	0.088% € 535.2k
Mario Polywka	Independent Non-Executive Director	7.2yrs	UK£201.69k	0.052% € 317.2k
Robert Ghenchev	Independent Non-Executive Director	4.5yrs	sin datos	sin datos
Franziska Michor	Independent Director	1.5yrs	UK£178.86k	0.028% € 168.7k

3.8yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RK se considera experimentada (3.8 años de antigüedad promedio).

Exscientia Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

Exscientia plc, Annual General Meeting, May 15, 2024

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Exscientia plc, Annual General Meeting, May 18, 2022

Recent updates

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Third quarter 2024 earnings released: UK£0.40 loss per share (vs UK£0.25 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.37 loss in 2Q 2023)

Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for approximately $640 million.

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) entered into a transaction agreement to acquire Exscientia plc (NasdaqGS:EXAI) for

New major risk - Revenue and earnings growth

The Schall Law Firm Announces Class Action Lawsuit Against Exscientia plc

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.38 loss in 1Q 2023)

Exscientia plc to Report Q1, 2024 Results on May 21, 2024

Holzer & Holzer, LLC Files Class Action Lawsuit on Behalf of Exscientia P.L.C. Investors

Exscientia plc, Annual General Meeting, May 15, 2024

New minor risk - Shareholder dilution

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Exscientia plc has filed a Follow-on Equity Offering in the amount of $150 million.

Full year 2023 earnings released: UK£1.18 loss per share (vs UK£0.97 loss in FY 2022)

Exscientia plc to Report Fiscal Year 2023 Results on Mar 21, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: UK£0.25 loss per share (vs UK£0.29 loss in 3Q 2022)

Exscientia plc to Report Q3, 2023 Results on Nov 09, 2023

Parker Moss to Join Exscientia as EVP, Corporate Development

Exscientia plc to Present New Preclinical Data for AI- Designed LSD1 and MALT1 Inhibitors at ESMO 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 2Q 2022)

Exscientia plc to Report Q2, 2023 Results on Aug 10, 2023

Exscientia plc Initiates Prospective Observational Study in Ovarian Cancer

Exscientia plc Announces First Patient Enrolled in Phase 1/2 ELUCIDATE Trial Assessing GTAEXS617 in Advanced Solid Tumours

First quarter 2023 earnings released: US$0.38 loss per share (vs US$0.17 loss in 1Q 2022)

Exscientia plc Highlights "The Future of AI-Enabled Drug Discovery" at SLAS Europe

Exscientia plc to Report Q1, 2023 Results on May 24, 2023

Exscientia plc Appoints Harvard Professor Franziska Michor to Board of Directors

Full year 2022 earnings released: UK£0.97 loss per share (vs UK£0.99 loss in FY 2021)

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Exscientia plc Highlights New Data to Identify Patients That Are More Likely to Respond to Its A2a Receptor Antagonist, Exs-21546

Exscientia plc Receives First clinical trial application Approval to Initiate IGNITE-AI, Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

Exscientia plc to Report Q3, 2022 Results on Nov 15, 2022

Blood Cancer Discovery Publication Further Validates Exscientia's Ai Precision Medicine Platform for Improving Patient Outcomes

Exscientia plc Welcomes Caroline Rowland as Chief People Officer

Second quarter 2022 earnings released: UK£0.23 loss per share (vs UK£0.71 loss in 2Q 2021)

Exscientia plc to Report Q2, 2022 Results on Aug 17, 2022

Exscientia plc Reports Data from EXS-21546 Phase 1A Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers

Exscientia plc to Report Q1, 2022 Results on May 25, 2022

Exscientia plc, Annual General Meeting, May 18, 2022

Exscientia plc Appoints Michael Krams as Chief Quantitative Medicine Officer

No independent directors

Third quarter 2021 earnings released: UK£0.059 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad